en · de · es · fr · pt
aod-9604-notes.peptides6579.com › Faq › Background And Development History — What the Evidence Shows

Background And Development History — What the Evidence Shows

By Editorial Desk · published 2025-10-21 · last reviewed 2025-12-03 · Faq

A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-12-03 and is reviewed periodically as new material appears.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Notes from published material

== Ligands == Until comparatively recently, there were few pharmacological tools for the study of δ receptors. As a consequence, our understanding of their function is much more limited than those of the other opioid receptors for which selective ligands have long been available. However, there are now several selective δ-opioid receptor agonists available, including peptides such as DPDPE and deltorphin II, and non-peptide drugs such as SNC-80, the more potent (+)-BW373U86, a newer drug DPI-287, which does not produce the problems with convulsions seen with the earlier agents, and the mixed μ/δ agonist DPI-3290, which is a much more potent analgesic than the more highly selective δ agonists. Selective antagonists for the δ receptor are also available, with the best known being the opiate derivative naltrindole.

As the urban area continued to expand, much of rural Scarborough was converted to suburban housing developments in the last third of the 20th century. At the start of the 21st century, growth occurred along the Highway 401 corridor at the northern end of the Scarborough RT; highrise condominium projects have increased the residential density around Scarborough City Centre. In 1988, there was a reorganization. The board of control was abolished. Alderman was changed to councillor. Six additional metro council positions were created and these were elected separately for the first time. Scarborough's council consisted of a mayor, 14 local councillors and six Metro councillors. In 1998, the municipality of Scarborough was dissolved and the district amalgamated with East York, Etobicoke, North York, York, and the old city of Toronto into the current city of Toronto.

== Economy == The territories of the Russian Partition saw very moderate economic growth over time. No business activity could take place without bribing the Tsarist officials first. Much of the output of the Polish Partition was exported to Russia proper, especially after the border between Congress Poland and Russia was abolished in 1851. The emancipation reform of 1861 was a major step towards industrialization and urbanization. Particularly, the last three or four decades before World War I saw significant economic development and urbanization. However, in many areas of the economy, development stalled.

Sources: en.wikipedia.org

Related pages on this site

Background from the literature

== Notable research == From 1994 to the present the Siuzdak lab has been working on activity metabolomics. using liquid chromatography mass spectrometry-based metabolomics to identify metabolites that alter phenotype. His initial efforts with Richard Lerner, used liquid chromatography mass spectrometry to perform metabolomic experiments on the cerebral spinal fluid of sleep deprived animals. cis-9,10-octadecenoamide, a novel lipid hormone (also known as oleamide), was observed and shown to have sleep inducing properties. This work is one of the earliest such experiments combining liquid chromatography mass spectrometry and metabolomics to identify active metabolites. Another notable activity metabolomics effort with Oscar Yanes (Spain) identified neuroprotectin D1 as a metabolite that promotes stem cell differentiation. In 1996 whole virus analysis was performed with an electrospray ionization mass spectrometer where the virus was collected and successfully tested for viability. Later, he and his collaborators provided the first example of a whole intact virus (tobacco mosaic virus) being mass measured using a charge detection mass spectrometer, an instrument designed by Henry Benner and Stephen Fuerstenau at Lawrence Berkeley National Labs. In 1999, the Siuzdak lab described the use of nanostructures to enhance desorption/ionization on porous silicon of small molecules (DIOS), this is also known as the first surface-based example of surface-assisted laser desorption/ionization mass spectrometry (SALDI-MS).

==== Regional air hubs ==== UPS has five large regional air hubs in the United States, located in Ontario, California; Dallas, Texas; Rockford, Illinois; Philadelphia, Pennsylvania; and Atlanta, Georgia. These hubs serve as centers for sorting, transfer and delivery of packages.

== Background == Even before the beginning of the war, the Mexican government showed its disapproval of fascist nations on multiple occasions. On November 6, 1935, Mexico joined the League of Nations economic blockades against the Kingdom of Italy for the invasion and subsequent annexation of the Ethiopian Empire. A few years later, on March 19, 1938, Mexico protested before the League of Nations against the violation of Austrian sovereignty after the Anschluss, whereas the United Kingdom, France, and the United States remained silent. The most famous case of Mexico's rejection of fascism was the recognition of the Spanish Republican government in exile. On June 17, 1939, the Mexican government withdrew its embassy from Spanish territory, leaving diplomatic affairs in the hands of the Cuban embassy. Since 1937, Spanish refugees (notably Republican supporters) had been arriving on Mexican shores and were received by the authorities in the Port of Veracruz, where ships loaded with Spaniards and some Jews persecuted in Europe by the Nazis arrived. During this period, Mexico's diplomatic relations with democratic nations were strained. Since the oil expropriation of 1938, the United Kingdom had broken off relations, and the United States maintained a commercial blockade against Mexico. In addition, the Soviet Union had withdrawn its ambassador since the Cardenista government gave political asylum to Leon Trotsky, who was a strong opponent of Joseph Stalin's regime.

Also Monte Rosa will receive $50m as an upfront payment and additional payments that will depend on the pre-clinical, clinical, commercial stages and sales, as well as multi-level royalty system and may exceed $2 billion. In March 2024, it was announced Roche had sold Genentech's site in Vacaville, California to the Swiss pharmaceutical company, Lonza for $1.2 billion. In November 2024, Roche acquired Poseida Therapeutics for US $1.0 billion. In April 2025, Roche announced it would invest $50 billion in the United States over the next five years, creating more than 12,000 new jobs. In May 2025, Genentech, a Roche subsidiary agreed a partnership worth $2.1 billion with Orionis Biosciences for the development of a small-molecule protein degrader for cancer. In October 2025, Roche announced the completion of its acquisition, for $3.5 billion, of 89bio, a San-Francisco based company focusing on developing therapies for liver and cardio-metabolic disease.

Sources: en.wikipedia.org

Further detail

There are special risks to consider for older adults, and women who are pregnant. When a person ages, the body becomes less able to rid itself of barbiturates. As a result, people over the age of 65 are at higher risk of experiencing the harmful effects of barbiturates, including drug dependence and accidental overdose. When barbiturates are taken during pregnancy, the drug passes through the placenta to the fetus. After the baby is born, it may experience withdrawal symptoms and have trouble breathing. In addition, nursing mothers who take barbiturates may transmit the drug to their babies through breast milk. A rare adverse reaction to barbiturates is Stevens–Johnson syndrome, which primarily affects the mucous membranes.

Transgenic mice with a fluorescently tagged UBE3A were used to test the effectiveness of unsilencing the paternal copy. When tested on mice in vivo, topotecan affected the hippocampus, striatum and cerebral cortex but not the cerebellum unless a higher dose was administered (21.6 micrograms/hour for five days). The study suggested that the topoisomerase inhibitors have the potential to produce a normally functioning UBE3A protein. Most symptoms due to Angelman syndrome are traditionally treated by speech therapy, physical therapy and occupational therapy. Anti-seizure medication is often prescribed as seizures are a common symptom of Angelman syndrome. These treatments target only symptoms. This drug has been administered to cancer patients. It was well tolerated when administered to pediatric and adult patients.

5-HTP robustly produces the head-twitch response (HTR) in rodents when administered at relatively high doses. It dose-dependently induces the HTR in mice across a dose range of 50 to 250 mg/kg via intraperitoneal administration, with an inverted U-shaped dose–response curve and maximal induction of the HTR at a dose of 200 mg/kg. Similarly to the case of 5-HTP, intracerebroventricular injection of serotonin, but not peripheral administration of serotonin, produces the HTR. The HTR is induced by serotonergic psychedelics like lysergic acid diethylamide (LSD) and psilocybin and is a behavioral proxy of psychedelic effects. The HTR of 5-HTP is blocked by serotonin 5-HT2A receptor antagonists, which block the hallucinogenic effects of serotonergic psychedelics in humans, is prevented by aromatic L-amino acid decarboxylase (AAAD) inhibitors, which block conversion of 5-HTP into serotonin, and is potentiated by monoamine oxidase A (MAO-A) inhibitors, which prevent the degradation of serotonin and other endogenous tryptamines. It is also suppressed by the serotonin 5-HT1A receptor full agonist 8-OH-DPAT, is greatly augmented by the serotonin 5-HT2C receptor antagonist RS-102221, and is reduced by the trace amine-associated receptor 1 (TAAR1) antagonist EPPTB.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network